Sight-restoring implant approved for sale in EEA
An implant designed to restore a degree of sight to people with advanced retinal degenerative diseases has been approved for sale in the European Economic Area (EEA).
The Argus II Retinal Prosthesis System was developed by Second Sight Medical Products, a US company whose European headquarters are in Lausanne, Switzerland.
After a clinical trial involving more than 30 blind patients, and a review of the product’s safety and performance by an independent expert body, the device is said to be the first approved treatment ever available for sightless people.
‘After years of research, we are… able to offer a viable long-term solution for people suffering from advanced retinal degenerative diseases such as retinitis pigmentosa [RP],’ said Robert Greenberg, managing director, president and chief executive officer of Second Sight. ‘The CE Mark approval… represents a huge step forward for the field and for these patients who have, until now, had no proven treatment alternatives.’
Argus II is Second Sight’s second-generation implantable device intended to treat profoundly blind people suffering from degenerative diseases such as RP.
Register now to continue reading
Thanks for visiting The Engineer. You’ve now reached your monthly limit of news stories. Register for free to unlock unlimited access to all of our news coverage, as well as premium content including opinion, in-depth features and special reports.
Benefits of registering
-
In-depth insights and coverage of key emerging trends
-
Unrestricted access to special reports throughout the year
-
Daily technology news delivered straight to your inbox
Radio wave weapon knocks out drone swarms
Probably. A radio-controlled drone cannot be completely shielded to RF, else you´d lose the ability to control it. The fibre optical cable removes...